5TH ANNUAL IMMUNO-ONCOLOGY BD&L AND INVESTMENT FORUM

Location: Waldorf Astoria Chicago Hotel, Chicago

Date: May 31, 2019

The 5th Annual Immuno-Oncology BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment.

China-US Partnering & Investment Panel

Echo Hindle-Yang – CEO of MSQ Ventures and a host of other experts in cross border investment and development strategies led the discussion onthe China-US Partnering & Investment Panel. The panlists provided insights into the novel oncology therapy landscape, the latest regulations and opportunities for early stage oncology companies to enter the Chinese market.

Co-Chaired by:

Guillaume Vignon, SVP BD, BeiGene, Ltd.

Helen Chen, MD and Head of China Life Sciences, L.E.K. Consulting 

Speakers：

Echo Hindle-Yang, Founder & CEO, MSQ Ventures

John Xu, Co-Founder & CEO, Jemincare Therapeutics Corp.

Ji Li, Venture Partner, Lilly Asia Ventures

Yuwan Liu, Founding Partner, BOHE Angel Fund

May Wang, SVP, Head of BD & Strategic Alliances, Hutchison China MediTech Ltd.  

During the China-US Partnering and Investment Panel, extended discussions range from "deal-making trends", "working with the Chinese", and "external/ political environment."

"Deal-making trends" focused on what value overseas biopharmaceutical companies can provide for Chinese companies and investors in the current environment. Specifically, China's healthcare industry continues to seek innovative technology from overseas to further expand their pipelines and business. Also, the panel commented on the current trends in healthcare investments, including the stage of the asset, therapeutic area, as well as the type of deal.

The section on "working with the Chinese" helped address Western companies’ doubts about what type of Chinese companies and funds might be the best to approach and work with for. Most importantly, understanding deal-making and negotiation strategies with a Chinese company are key to achieve the ultimate business goals.

"External/ political environment" introduced the audience to how the HKSE and the New Shanghai Science and Technology Board may affect the deal-making progress and investments. In addition, this section of the panel provided some guidance on how to navigate in face of the trade tensions between the US and China.

Plenary & Therapeutic Sessions Highlight:

-        Industry Roundtable

-        Pharma-Bio Dealmaking Panel

-        Revised Strategies for Advanced Therapeutics Panel

-        Latest Advances in Cell & Gene Therapies Panel

-        China-US Partnering & Investment Panel

-        Innovation Panel

-        Investor Discussion